The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders. These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been suggested that the persisting therapeutic effects of psychedelics are attributable to a similar biological mechanism (39, 40).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [39]
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“5 mg per kg), and this effect was sustained for at least 72 hour”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Dissociative anaesthetics mimic the positive and the negative symptoms (social withdrawal and apathy) of schizophrenia through antagonism at NMDA ( N -methyl- D -aspartate) glutamate receptor”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Systemic administration of non-competitive NMDA antagonists, such as ketamine, PCP and MK-801 (also known as dizocilpine), in rats markedly increases glutamate release in the mPF”
BackgroundDavis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“and was rated as among the most personally meaningful experience”
Background(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
(2009) · Elsevier eBooks · doi:10.1016/c2009-1-03742-3 · Cited by 1,308
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“These effects are probably due to a blockade of NMDA receptors on GABA (γ-aminobutyric acid)-ergic interneuron”
Background
Research works printed but not linked: 6
- Hofmann, A. in Chemical Constitution and Pharmacodynamic Actions (ed. Burger, A.) 169–235 (M.Dekker, New York, 1968).
- Dittrich, A. in 50 Years of LSD. Current Status and Perspectives of Hallucinogens (eds Pletscher, A. & Ladewig, D.) 101–118 (Parthenon, New York, 1994).
- Hoffer, A. in The Uses and Implications of Hallucinogenic Drugs (eds Aaronson, B. & Osmond, H.) 357–366 (Hogarth Press, London, 1970).
- Leuner, H. in 50 Years of LSD: Current Status and Perspectives of Hallucinogen Research (eds Pletscher, A. & Ladewig, D.) 175–189 (Parthenon, New York, 1994).
- Crocket, R., Sandison, R. A. & Walk, A. in Proc. R. Med–Psychol. Assoc. (Lewis & Co., London, 1963).
- Leuner H. in Ethnopsychotherapie (eds Dittrich, A. & Scharfetter, C.) 151–161 (Enke, Stuttgard, 1987)
Cited by
Items 201–300 of 721
Animal models for predicting the efficacy and side effects of antipsychotic drugs
Gobira, P. H., Röpke, J., de Aguiar, D. C., Crippa, J. A. S., & Moreira, F. A. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1164 · Cited by 65
Varker, T., Watson, L., Gibson, K., Forbes, D., & O'Donnell, M. L. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1817639 · Cited by 74
“Ketamine acts primarily on the glutamatergic system (Vollenweider and Kometer 2010), which has been implicated in the formation of traumatic memory, mediation of the stress response, and pathophysiology of PTSD (Feder et al. 2014).”
BackgroundElsey, J. W. B. (2017) · Drug Science Policy and Law · doi:10.1177/2050324517723232 · Cited by 57
“…(5-HT2A) receptors (Carhart-Harris et al., 2012; Tagliazucchi et al., 2016), corroborating animal and human research indicating that psychedelic drugs act primarily through agonistic activity at 5-HT2A receptors (Glennon et al., 1984; see Nichols, 2004; Vollenweider and Kometer, 2010 for reviews).”
BackgroundClose, J. B., Hajien, E. C., Watts, R., Roseman, L., & Carhart-Harris, R. L. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2020.01.005 · Cited by 54
Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies
Ross, S. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.04.002 · Cited by 55
Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects
Li, M., Woelfer, M., Čolić, L., Safron, A., Chang, C., Heinze, H., Speck, O., Mayberg, H. S., Biswal, B. B., Salvadore, G., et al. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0942-y · Cited by 60
Chen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106837 · Cited by 52
Sabé, M., Sulstarova, A., Glangetas, A., Pieri, M. D., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L. E., Seragnoli, F., Thorens, G., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02800-5 · Cited by 71
“Nevertheless, ethical considerations underscore the imperative that individuals within the schizophrenia-spectrum disorder, possessing a history of aggressive or suicidal behavior during psychotic episodes, should not undergo exposure to this therapeutic intervention.”
Riga, M. S., Lladó-Pelfort, L., Artigas, F., & Celada, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.049 · Cited by 53
“Similar actions have been reported after ketamine administration (Vollenweider and Kometer, 2010), a non-competitive NMDA-R antagonist with proven efficacy in treatment-resistant depression (Zarate et al.”
BackgroundResultBurt, J. B., Preller, K. H., Demirtas, M., Ji, J. L., Krystal, J. H., Vollenweider, F. X., Anticevic, A., & Murray, J. D. (2021) · eLife · doi:10.7554/elife.69320 · Cited by 53
Self-citationRegion-specific glutamate changes in patients with unipolar depression
Grimm, S., Luborzewski, A., Schubert, F., Merkl, A., Kronenberg, G., Colla, M., Heuser, I., & Bajbouj, M. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.04.018 · Cited by 52
The neurophysiology of ketamine: an integrative review
McMillan, R. L., & Muthukumaraswamy, S. D. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0090 · Cited by 54
Psychedelics and creativity: a review of the quantitative literature
Baggott, M. J. (2015) · doi:10.7287/peerj.preprints.1202v1 · Cited by 50
A neurobiological perspective on social influence: Serotonin and social adaptation
Duerler, P., Vollenweider, F. X., & Preller, K. H. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15607 · Cited by 53
“In human and rodent studies Psi also showed downstream effects on the DA level in the VS in humans (Puig et al., 2003; Vollenweider, 1999; Vollenweider & Kometer, 2010).”
BackgroundSelf-citationLysergic acid diethylamide: a drug of ‘use’?
Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316640440 · Cited by 58
“These serotoninbased dynamics are directly relevant to treat addiction because in addicted individuals, serotonin levels are usually low, and serotonin also modulates other neurotransmitter systems [Winkelman, 2014; Ray, 2010; Glennon et al. 1984; Halberstadt, 2015; Nichols, 2004; Vollenweider and Kometer, 2010].”
Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice
Buchborn, T., Lyons, T., & Knöpfel, T. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00017 · Cited by 51
“…serotonergic hallucinogens such as lysergic acid diethylamide (LSD) (Kraehenmann et al., 2017), and more specifically, 5-HT2A receptors of layer 5 pyramidal cells are thought to be a key mediator of psychedelic activity (Vollenweider and Kometer, 2010; Muthukumaraswamy et al., 2013; Nichols, 2016).”
BackgroundMotives for Classical and Novel Psychoactive Substances Use in Psychedelic Polydrug Users
Kettner, H., Mason, N. L., & Kuypers, K. P. C. (2019) · Contemporary Drug Problems · doi:10.1177/0091450919863899 · Cited by 55
“The aim of the present study was to investigate and compare motives for the use of legal psychoactive substances (LPS, alcohol, nicotine), CPS (cannabis, MDMA, amphetamines, cocaine, psilocybin, LSD and ayahuasca), and NPS within a functional framework, extending previously identified motivational domains.”
InfluentialMagaraggia, I., Kuiperes, Z., & Schreiber, R. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107467 · Cited by 49
“This class of compounds includes lysergic acid diethylamide (LSD), n,ndimethyltryptamine (DMT), and psilocybin, which act as (non-selective) agonists at the serotonin 2a receptor (5-HT2AR) (Ray, 2010; Vollenweider & Kometer, 2010).”
BackgroundRosa, W. E., Sager, Z. S., Miller, M. E., Bernstein, I., Rinaldi, A. D., Addicott, K., Ljuslin, M., Adrian, C., Back, A. L., Beachy, J., et al. (2022) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0036 · Cited by 54
Psilocybin Therapeutic Research: The Present and Future Paradigm
Kargbo, R. B. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00048 · Cited by 54
Sweat, N. W., Bates, L. W., & Hendricks, P. S. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1234090 · Cited by 48
“…or simply administer the substance assuming a purely neurobiological mechanism of action (e.g., changes to the Default Mode Network (DMN), neuroplastic adaptation, or increase in size and number of dendritic spines (Bouso et al. 2015; Carhart-Harris et al. 2014; Vollenweider and Kometer 2010).”
BackgroundPsilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia
Brogaard, B. “., & Gatzia, D. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00083-2 · Cited by 50
Breeksema, J. J., Niemeijer, A. R., Kuin, B., Veraart, J. K. E., Kamphuis, J., Schimmel, N., van den Brink, W., Vermetten, E. H. G. J. M., & Schoevers, R. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.948115 · Cited by 53
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A., Piolino, P., & Benyamina, A. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106086 · Cited by 68
Multistage drug effects of ketamine in the treatment of major depression
Walter, M., Li, S., & Demenescu, L. R. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0535-3 · Cited by 50
“For the ACC, particularly high increases have been shown for anterior midcingulate and subgenual portions [115], which have the highest NMDA receptor densities along the cingulate cortex [118].”
BackgroundSchindler, E. A. D., Wallace, R. M., Sloshower, J. A., & D’Souza, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00177 · Cited by 47
“Additional systems associated with the action of psychedelics are dopaminergic, glutamatergic, and GABAergic systems (Vollenweider and Kometer, 2010; Nichols, 2016; Martin and Nichols, 2017).”
BackgroundScalable Hybrid Synthetic/Biocatalytic Route to Psilocybin
Fricke, J., Kargbo, R., Regestein, L., Lenz, C., Peschel, G., Rosenbaum, M. A., Sherwood, A., & Hoffmeister, D. (2020) · Chemistry – A European Journal · doi:10.1002/chem.202000134 · Cited by 46
Rantamäki, T., & Kohtala, S. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018697 · Cited by 45
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Urban, M. M., Stingl, M., & Meinhardt, M. W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1156319 · Cited by 46
“Adaptation of 5HT2AR density in prefrontal areas could constitute another important effect of psychedelic action (Vollenweider and Kometer, 2010; Bogenschutz and Johnson, 2016).”
BackgroundLiester, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107120522 · Cited by 45
“For example, Obsessive-Compulsive Disorder (OCD) and depression have been suggested to respond to treatment with LSD [77-79].”
BackgroundKałużna, A., Schlosser, M., Craste, E. G., Stroud, J., & Cooke, J. E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00199 · Cited by 62
“Serotonin 2A receptor (5-HT 2A R) agonists, also known as classic psychedelics (Vollenweider & Kometer, 2010), have been utilized by humans for millennia.”
Kargieman, L., Riga, M. S., Artigas, F., & Celada, P. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.249 · Cited by 45
“This pattern of action is similar to that observed in recent human neuroimaging studies with ketamine (Vollenweider and Kometer, 2010).”
ResultJalal, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5042-1 · Cited by 56
Hayes, S. C., Law, S., Malady, M., Zhu, Z., & Bai, X. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.005 · Cited by 56
Sahib, A. K., Loureiro, J. R. A., Vasavada, M. M., Kubicki, A., Joshi, S. H., Wang, K., Woods, R. P., Congdon, E., Wang, D. J. J., Boucher, M. L., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.017 · Cited by 43
Vejmola, Č., Tylš, F., Piorecká, V., Koudelka, V., Kadeřábek, L., Novák, T., & Páleníček, T. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01603-4 · Cited by 41
Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review
Lazur, J., Hnatyk, K., Kała, K., Sułkowska‐Ziaja, K., & Muszyńska, B. (2023) · Antioxidants · doi:10.3390/antiox12030623 · Cited by 46
“Microdoses do not induce hallucinations, contrary to the regular dose used for recreational use [87].”
BackgroundLiebe, T., Li, M., Čolić, L., Munk, M. H. J., Sweeney‐Reed, C. M., Woelfer, M., Kretzschmar, M., Steiner, J., von Düring, F., Behnisch, G., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.09.001 · Cited by 48
Passie, T., Adams, H.-A., Logemann, F., Brandt, S. D., Wiese, B., & Karst, M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.01.005 · Cited by 48
Eleftheriou, M. E., & Thomas, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707057 · Cited by 39
““Classical” serotonergic psychedelics, including psilocybin and LSD, act as agonists on the serotonin system, with relative selectivity for the 5HT2A receptor (24), whilst dissociative psychedelics, such as ketamine, hijack the glutamatergic system, acting as NMDAR antagonists (25).”
BackgroundMotives for the use of serotonergic psychedelics: A systematic review
Basedow, L. A., & Kuitunen‐Paul, S. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13480 · Cited by 48
Lake, S., & Lucas, P. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104507 · Cited by 49
Carhart-Harris, R., Brugger, S., Nutt, D., & Stone, J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113494107 · Cited by 41
“, 2005); however, despite considerable historical interest (Osmond and Smythies, 1952), they have fallen out of favour in recent years, as focus has shifted more on to their therapeutic potential (Vollenweider and Kometer, 2010).”
BackgroundKetamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 43
“In the 1950s, psychedelic drugs, such as lysergic acid diethylamide (LSD), were reported to enhance self-awareness and facilitate the recall of emotional memories, providing considerable benefits to psychotherapy [22].”
BackgroundBeaussant, Y., Sanders, J. J., Sager, Z. S., Tulsky, J. A., Braun, I. M., Blinderman, C. D., Bossis, A. P., & Byock, I. R. (2020) · Journal of Palliative Medicine · doi:10.1089/jpm.2019.0603 · Cited by 48
Systematic review of psychometric instruments used in research with psychedelics
de Deus Pontual, A. A., Senhorini, H. G., Corradi-Webster, C. M., Tófoli, L. F., & Daldegan-Bueno, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2079108 · Cited by 36
“…capacities related to mindfulness (Soler et al. 2016) and even possible therapeutic uses, such as tools in the treatment of depression (PalhanoFontes et al. 2019), mood disorders (Vollenweider and Kometer 2010) or problematic drug use (Sessa and Johnson 2015) are being investigated and tested.”
BackgroundLafrance, A., Strahan, E., Bird, B. M., St. Pierre, M., & Walsh, Z. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211048049 · Cited by 40
“The effects of psychedelics are diverse and varied but most are described as inducing altered perception of time and space, a feeling of interconnectivity and oneness, and affective introspection (Griffiths et al., 2006; Johnson et al., 2008; Vollenweider & Kometer, 2010).”
BackgroundToward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans
Moujaes, F., Preller, K. H., Ji, J. L., Murray, J. D., Berkovitch, L., Vollenweider, F. X., & Anticevic, A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.021 · Cited by 40
Self-citationTroyano‐Rodriguez, E., Lladó-Pelfort, L., Santana, N., Teruel‐Martí, V., Celada, P., & Artigas, F. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.019 · Cited by 46
The fibrinolytic system: A new target for treatment of depression with psychedelics
Idell, R. D., Florova, G., Komissarov, A. A., Shetty, S., Girard, R., & Idell, S. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.01.013 · Cited by 41
“Psilocybin and other serotonergic classic psychedelics have been shown to exert their effects through agonism at the 5-ht2a subtype of the serotonin receptor [74], which is associated not only with psilocybin’s psychedelic effects, but also with vascular smooth muscle contraction, platelet aggregation, thrombus format…”
BackgroundGonçalves, J., Luís, Â., Gallardo, E., & Duarte, A. P. (2021) · Molecules · doi:10.3390/molecules26051397 · Cited by 52
“In addition, these compounds can also increase the release of glutamate, which activates receptors such as N-methyl-d-aspartic acid receptors and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors [50,132].”
BackgroundPsilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice
Thomas, C. W., Blanco‐Duque, C., Bréant, B. J. B., Goodwin, G. M., Sharp, T., Bannerman, D. M., & Vyazovskiy, V. V. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01846-9 · Cited by 52
“The psychedelic state is widely suggested to promote neuroplasticity, which is theorised to be important for psilocybin’s therapeutic efficacy [26].”
BackgroundExpectation creates something out of nothing: The role of attention in iconic memory reconsidered
Aru, J., & Bachmann, T. (2017) · Consciousness and Cognition · doi:10.1016/j.concog.2017.06.017 · Cited by 46
Jones, G. M., & Nock, M. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211066714 · Cited by 43
“…of psilocybin—downregulation of the serotonin 2A receptor—may underlie the effects observed here (Mahapatra and Gupta, 2017; Van Oekelen et al., 2003; Vollenweider and Kometer, 2010), although future studies are needed to better understand whether and how psilocybin may prospectively reduce the…”
BackgroundLSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice
Alper, K., Dong, B., Shah, R., Sershen, H., & Vinod, K. Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00994 · Cited by 38
Healy, C. J., Lee, K. A., & D'Andrea, W. M. (2021) · Chronic Stress · doi:10.1177/24705470211029881 · Cited by 47
IUPHAR – invited review - Ibogaine – A legacy within the current renaissance of psychedelic therapy
Mash, D. C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106620 · Cited by 45
Role of psilocybin in the treatment of depression
Mahapatra, A., & Gupta, R. G. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316676092 · Cited by 44
“2008] and because of its novel mechanism of 5-HT2A serotonin receptor agonism, it is being explored for therapeutic utility in mood and anxiety disorders [Vollenweider and Kometer, 2010].”
BackgroundVolgin, A. D., Yakovlev, O. A., Demin, K. A., Alekseeva, P. A., Kyzar, E. J., Collins, C. J., Nichols, D. E., & Kalueff, A. V. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00433 · Cited by 43
Brys, I., Barrientos, S. A., Ward, J. E., Wallander, J., Petersson, P., & Halje, P. (2023) · Communications Biology · doi:10.1038/s42003-023-05093-6 · Cited by 42
The role of setting for ketamine abuse: clinical and preclinical evidence
De Luca, M. T., Meringolo, M., Spagnolo, P. A., & Badiani, A. (2012) · Reviews in the Neurosciences · doi:10.1515/revneuro-2012-0078 · Cited by 37
Argento, E., Braschel, M., Walsh, Z., Socias, M. E., & Shannon, K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798610 · Cited by 37
“Evidence suggests that opioid use, as well as major depression and suicide, is associated with increased binding of 5-HT2A receptors, while psychedelics down-regulate these receptors (Anisman et al., 2008; Bogenschutz and Johnson, 2015; Müller and Homberg, 2015; Vollenweider and Kometer, 2010).”
Losing the Self in Near-Death Experiences: The Experience of Ego-Dissolution
Martial, C., Fontaine, G. P., Gosseries, O., Carhart-Harris, R. L., Timmermann, C., Laureys, S., & Cassol, H. (2021) · Brain Sciences · doi:10.3390/brainsci11070929 · Cited by 50
“, 5-HT2A receptor agonists) such as psilocybin [21,22] and N, N-Dimethyltryptamine (DMT) [23], as well as dissociative anesthetics such as ketamine [24], and the terpene salvinorin–A [25].”
BackgroundStrumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 48
“Finally, suicide has been associated with lower cortical thickness, a decreased number of dendritic spines, and the atrophy of neurons in the PFC [88,89].”
BackgroundInfluentialSpain, A., Howarth, C., Khrapitchev, A. A., Sharp, T., Sibson, N. R., & Martin, C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.018 · Cited by 37
“This approach has recently been applied to psilocybin, the active constituent of “magic” mushrooms; which is of interest due to its potential utility in treating affective disorders (Carhart-Harris et al., 2012a, 2012b; Grob et al., 2011; Vollenweider and Kometer, 2010).”
BackgroundMethodBehavioral Animal Models of Antipsychotic Drug Actions
Peleg‐Raibstein, D., Feldon, J., & Meyer, U. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_14 · Cited by 41
Molecular and Cellular Mechanisms of Antidepressant Action
Sharp, T. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_216 · Cited by 36
“Moreover, there are ongoing clinical trials into the antidepressant potential of psychedelic drug, psilocybin, reinforced by evidence that a 5-HT2 receptor agonist action may evoke changes in neural plasticity to produce long-lasting improvement in mood (Vollenweider and Kometer 2010).”
Ingram, R., Kang, H., Lightman, S., Jane, D. E., Bortolotto, Z. A., Collingridge, G. L., Lodge, D., & Volianskis, A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.008 · Cited by 36
“It is generally believed that their agonist effect on 5-HT2 receptors, particularly 5-HT2A receptors, is the basis for their psychedelic effects (Nichols, 2004; Vollenweider and Kometer, 2010).”
InfluentialThe Treatment of Substance Use Disorders: Recent Developments and New Perspectives
Rosenthal, A., Ebrahimi, C., Wedemeyer, F., Romanczuk‐Seiferth, N., & Beck, A. (2022) · Neuropsychobiology · doi:10.1159/000525268 · Cited by 49
Affect/Emotion Induction Methods
FakhrHosseini, S., & Jeon, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801851-4.00010-0 · Cited by 57
Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence
Deurwaerdère, P. D., Chagraoui, A., & Giovanni, G. D. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.02.001 · Cited by 46
Psilocybin’s effects on cognition and creativity: A scoping review
Bonnieux, J. N., VanderZwaag, B., Premji, Z., Garcia‐Romeu, A., & García-Barrera, M. A. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179801 · Cited by 39
“Psilocin’s psychedelic effects are primarily a result of it binding to the 5-HT2A receptor on neurons, thereby triggering increases in brain activity (Vollenweider and Kometer, 2010; Vollenweider et al., 1998) and network connectivity (Daws et al.”
BackgroundBraun, D., Rosenberg, A. M., Rabaniam, E., Haruvi, R., Malamud, D., Barbara, R., Aiznkot, T., Levavi‐Sivan, B., & Kawashima, T. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02391-7 · Cited by 41
“Such common mechanisms can occur at neural circuit levels and molecular levels [12, 88].”
BackgroundEffects of LSD on grooming behavior in serotonin transporter heterozygous (Sert) mice
Kyzar, E. J., Stewart, A., & Kalueff, A. V. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.08.018 · Cited by 35
Psychedelic medicine: The biology underlying the persisting psychedelic effects
Kuypers, K. P. C. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.02.029 · Cited by 35
Castelhano, J., Lima, G., Teixeira, M., Soares, C., Pais, M. L., & Castelo-Branco, M. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739053 · Cited by 48
Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder
Geldenhuys, C., van den Heuvel, L. L., Steyn, P., & Seedat, S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00929-x · Cited by 39
“This receptor activity has been found to be elevated in individuals coping with stress, thus down-regulation of prefrontal 5-HT2A receptors may be a putative therapeutic target [121].”
BackgroundPsychedelics in the treatment of unipolar and bipolar depression
Bosch, O. G., Halm, S., & Seifritz, E. (2022) · International Journal of Bipolar Disorders · doi:10.1186/s40345-022-00265-5 · Cited by 41
“Classic psychedelics modulate different neuronal networks that process sensory perception, the experience of self, and emotion regulation, which are relevant for the neurobiology of depression (Vollenweider and Kometer, 2010; Vollenweider and Preller, 2020).”
BackgroundBeyond the psychedelic hype: Exploring the persistence of the neoliberal paradigm
Davies, J., Pace, B. A., & Devenot, N. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00273 · Cited by 40
A Brief Historical Overview of Psychedelic Research
Geyer, M. A. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.11.003 · Cited by 53
Smith, D. A., Bailey, J. M., Williams, D., & Fantegrossi, W. E. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219337 · Cited by 35
“Introduction Hallucinogenic effects exerted by classic ergoline-, phenethylamine-, or tryptamine-derived drugs are currently understood to be mediated by agonist actions at serotonin 5-hydroxytryptamine 2A (5-HT2A) receptors (Nichols, 2004; Halberstadt, 2014), a site also implicated in numerous…”
BackgroundRiga, M. S., Bortolozzi, A. A., Campa, L., Artigas, F., & Celada, P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.016 · Cited by 41
“Moreover, some of these agents were marketed in the past (e.g. LSD) as a therapeutic aid in psychoanalysis, and there is a growing interest in their therapeutic use for the treatment of mood and anxiety disorders (Vollenweider and Kometer, 2010).”
Decreased Thalamocortical Connectivity in Chronic Ketamine Users
Liao, Y., Tang, J., Liu, J., Xie, A., Yang, M., Johnson, M., Wang, X., Deng, Q., Chen, H., Xiang, X., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167381 · Cited by 35
Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Prouzeau, D., Conejero, I., Voyvodic, P. L., Bécamel, C., Abbar, M., & López‐Castromán, J. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01361-0 · Cited by 40
Fluorine in psychedelic phenethylamines
Trachsel, D. (2012) · Drug Testing and Analysis · doi:10.1002/dta.413 · Cited by 34
Davis, A. K., Xin, Y., Sepeda, N. D., & Averill, L. A. (2023) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2023.2220874 · Cited by 43
“In recent years, there has been increasing interest in investigating the use of psychedelic medicines as adjuncts in the treatment of various psychiatric conditions, including depression and anxiety (22,23), obsessive-compulsive disorder (24), substance use disorders (25–28), and PTSD (29–32).”
BackgroundMcIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 37
Amat-Foraster, M., Jensen, A. A., Plath, N., Herrik, K. F., Celada, P., & Artigas, F. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.022 · Cited by 35
“In contrast, neuroimaging studies in humans and non-human primates show that ketamine increases glucose metabolism in the cingulate cortex and the thalamus (De Simoni et al., 2013; Downey et al., 2016; Doyle et al., 2013; Maltbie et al., 2016; Vollenweider and Kometer, 2010).”
Negative Allosteric Modulators of mGlu7 Receptor as Putative Antipsychotic Drugs
Cieślik, P., Woźniak, M., Kaczorowska, K., Brański, P., Burnat, G., Chocyk, A., Bobula, B., Gruca, P., Litwa, E., Pałucha-Poniewiera, A., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00316 · Cited by 33
Sexton, J. D., Crawford, M. S., Sweat, N. W., Varley, A. L., Green, E. E., & Hendricks, P. S. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119827796 · Cited by 38
Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 41
“, 2018) accompanied by extensive study of their neurobiological mechanisms of action (Vollenweider and Kometer, 2010; Nichols, 2016; Heal et al., 2018).”
Sinha, J. K., Trisal, A., Ghosh, S., Gupta, S., Singh, K. K., Han, S. S., Mahapatra, M., Abomughaid, M. M., Abomughayedh, A. M., Almutary, A. G., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102211 · Cited by 32
MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor
Puxty, D. J., Ramaekers, J. G., de la Torre, R., Farré, M., Pizarro, N., Pujadas, M., & Kuypers, K. P. C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00455 · Cited by 32
“It is generally assumed that the hallucinogenic actions of classical psychedelics arise from their action on the serotonin 2A (5-HT2A) receptor (Glennon et al., 1984; Vollenweider and Kometer, 2010).”
BackgroundBygrave, A. M., Kilonzo, K., Kullmann, D. M., Bannerman, D. M., & Kätzel, D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00835 · Cited by 43
“Given the frequent occurrence of rigidity, mutism, or dystonia (83), there might be parallels to catatonic schizophrenia (a sub-category, which has, however, been separated from schizophrenia in DSM-V), but, overall, NMDAR encephalitis appears to extend beyond and is not a perfect match for schizophrenia (86).”
BackgroundPearson, C. S., Siegel, J. S., & Gold, J. A. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120096 · Cited by 36
Young, S. N. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120128 · Cited by 30
Amat-Foraster, M., Celada, P., Richter, U., Jensen, A. A., Plath, N., Artigas, F., & Herrik, K. F. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107745 · Cited by 34
“neuroimaging studies in rodent, primate and human brains supporting the notion that ketamine analogously to PCP mediates activation of cortical and thalamic areas (Chin et al., 2011; Downey et al., 2016; Maltbie et al., 2016; Vollenweider and Kometer, 2010).”
BackgroundTricklebank, M. D., Robbins, T. W., Simmons, C., & Wong, E. H. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05787-x · Cited by 33
Molecular targets of psychedelic‐induced plasticity
Jaster, A. M., Revenga, M. D. L. F., & González‐Maeso, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15536 · Cited by 36
“…psychedelics, particularly naturally occurring compounds such as psilocybin and DMT in the ayahuasca brew, also behave as rapid- acting antidepressant medications (Carhart- Harris et al., 2016, 2021; Davis et al., 2020; Griffiths et al., 2016; Kyzar et al., 2017; Vollenweider & Kometer, 2010).”
BackgroundCruz, S. L., & Domínguez, M. (2011) · Substance Use & Misuse · doi:10.3109/10826084.2011.580222 · Cited by 32
“Also, drugs like lysergic acid diethylamide (LSD), psilocybin, mescaline, ketamine, and phencyclidine (PCP) produce both illusions and hallucinations (Mehling, 2003; Nichols, 2004; Vollenweider & Kometer, 2010).”
Background
Metadata
- Authors
- Vollenweider, F. X., & Kometer, M.
- Affiliations
- University of Zurich (CH)
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, Franz X.
- Venue
- Nature Reviews Neuroscience
- Published
- 2010-08-18
- Volume
- 11
- Issue
- 9
- Pages
- 642-651
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2068751924
- Semantic Scholar
- d95a57f4b1e3288f21a7dab08ebc2fd5ff10a762
- Cited by
- 723
- References
- 149
- Citations by year
- 2026: 55 · 2025: 75 · 2024: 55 · 2023: 64 · 2022: 53 · 2021: 63 · 2020: 50 · 2019: 35 · 2018: 56 · 2017: 37 · 2016: 48 · 2015: 29 · 2014: 24 · 2013: 18 · 2012: 25
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psychedelics, mood disorders, serotonergic system, glutamatergic system, dissociative anesthetics, LSD, psilocybin, ketamine, neuroplasticity, neural circuits, psychiatric treatment
- MeSH terms
- Animals, Brain, Hallucinogens, Humans, Models, Neurological, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.